Single and multiple doses of Indacaterol, a novel once-daily β2-agonists, are well tolerated in patients with mild asthma

被引：0
|
作者：
Brookman, L
Knight, H
Wood, J
Perry, S
Tarral, A
Elharrar, B
Pascoe, S
机构：
[1] Novartis Horsham Res Ctr, Horsham, W Sussex, England
[2] Biotrial, Paris, France
[3] Aster Cephac, Paris, France
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2006年 / 117卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2005.12.333
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
324
引用
收藏
页码：S83 / S83
页数：1
相关论文
共 50 条
  • [11] Turning a Molecule into a Medicine: the Development of Indacaterol as a Novel Once-Daily Bronchodilator Treatment for Patients with COPD
    Murphy, Lorraine
    Rennard, Stephen
    Donohue, James
    Molimard, Mathieu
    Dahl, Ronald
    Beeh, Kai-Michael
    Dederichs, Juergen
    Fuelle, Hans-Juergen
    Higgins, Mark
    Young, David
    DRUGS, 2014, 74 (14) : 1635 - 1657
  • [12] Tolerability of indacaterol, a novel once-daily β2-agonist, in patients with asthma:: a randomized, placebo-controlled, 28-day safety study
    Yang, William H.
    Martinot, Jean Benoit
    Pohunek, Petr
    Beier, Jutta
    Magula, Daniel
    Cameron, Ray
    Owen, Roger
    Higgins, Mark
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2007, 99 (06) : 555 - 561
  • [13] EFFICACY OF ONCE-DAILY EXTENDED-RELEASE THEOPHYLLINE IN DECREASING THE USE OF INHALED BETA(2)-AGONISTS IN STABLE, MILD-TO-MODERATE ASTHMA PATIENTS
    EDWARDS, TB
    DOCKHORN, RJ
    WAGNER, DE
    FIDDES, RA
    GROSSMAN, J
    MENENDEZ, R
    SOUTHERN, DL
    CEFALI, EA
    HASSANEIN, RS
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1995, 75 (05) : 409 - 416
  • [14] Multiple, Once-Daily, Oral Doses of 170 mg Atogepant for 28 Days are Safe and Well Tolerated With No Clinically Significant Effect on Alanine Aminotransferase in Healthy Adults
    Min, K.
    Kraft, W. K.
    Bondiskey, P.
    Colon-Gonzalez, F.
    Liu, W.
    Xu, J.
    Panebianco, D.
    Mixson, L.
    Dockendorf, M. F.
    Matthews, C. Z.
    Boinpally, R.
    HEADACHE, 2020, 60 : 30 - 31
  • [15] LONG-TERM EFFECTS OF ONCE-DAILY MOMETASONE FUROATE, TWICE-DAILY FLUTICASONE PROPIONATE, AND ONCE-DAILY MONTELUKAST ON BONE MINERAL DENSITY IN PATIENTS WITH MILD ASTHMA
    Maspero, J.
    Backer, V.
    Yao, R.
    Teper, A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (05) : A41 - A41
  • [16] ONCE-DAILY TIOTROPIUM RESPIMAT® ADD-ON TO INHALED CORTICOSTEROIDS ± LONG-ACTING β2-AGONISTS IMPROVES LUNG FUNCTION AND ASTHMA CONTROL AND REDUCES RISK OF ASTHMA WORSENING IN PATIENTS WITH MODERATE OR SEVERE ASTHMA.
    Murphy, K.
    Bensch, G.
    Berger, W. E.
    Engel, M.
    Schmidt, H.
    Moroni-Zentgraf, P.
    Kerstjens, H. A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2014, 113 (05) : A107 - A107
  • [17] Once-daily administration of budesonide Turbuhaler® was as effective as twice-daily treatment in patients with mild to moderate persistent asthma
    Mintz, S
    Alexander, M
    Li, JHS
    Mayer, PV
    JOURNAL OF ASTHMA, 2002, 39 (03) : 203 - 210
  • [18] Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary disease
    Geake, James B.
    Dabscheck, Eli J.
    Wood-Baker, Richard
    Cates, Christopher J.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (01):
  • [19] Once-daily sitagliptin monotherapy provides effective glycemic control over 54 weeks and is well tolerated in patients with type 2 diabetes
    Aschner, Pablo
    Lunceford, Jared
    Williams-Herman, Debora
    DIABETES, 2007, 56 : A553 - A553
  • [20] EFFECTS OF ONCE-DAILY MOMETASONE FUROATE ON BONE MINERAL DENSITY AT DIFFERENT LOCI IN PATIENTS WITH MILD ASTHMA
    Teper, A.
    Backer, V.
    Maspero, J.
    Yao, R.
    Staudinger, H.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (05) : A41 - A41
12345